
CLAIMS

1. A use of an effective amount of a compound of Formula I:



Formula I


wherein R_1, R_2, R_3, R_4, and R_5 are selected from H, halogen, halogenated C_{1-4} alkyl, and cyano; and

R_6 is H;

or a pharmaceutically acceptable salt, prodrug, or pharmaceutically acceptable salt prodrug thereof,

in the manufacture of a medicament for treatment or prophylaxis of transplant rejection, inhibiting rejection of transplanted biological material, or prophylaxis, treatment, or control of edema consequent to a transplant.

2. A use of a compound of Formula I



Formula I


wherein R_1, R_2, R_3, R_4, and R_5 are selected from H, halogen, halogenated C_{1-4} alkyl, and cyano; and

R_6 is H;

or a pharmaceutically acceptable salt, prodrug, or pharmaceutically acceptable salt prodrug thereof,

in the manufacture of a product for the preservation of a cell, tissue, or organ.

3. A use of a compound of Formula I



Formula I

wherein R_1, R_2, R_3, R_4, and R_5 are selected from H, halogen, halogenated C_{1-4} alkyl, and

cyano; and


R_6 is H;

or a pharmaceutically acceptable salt, prodrug, or pharmaceutically acceptable salt prodrug thereof,


in the manufacture of a product for protecting a heart during heart surgery.

4. The use of any one of claims 1-3, wherein R_1 is selected from trifluoromethyl, chloro, fluoro, and bromo; R_3 and R_5 are the same or different and selected from trifluoromethyl, chloro, fluoro, and bromo; and R_2 and R_4 are both H.

5. The use of claim 4, wherein the compound of Formula I is selected from:




and




or a pharmaceutically acceptable salt thereof.

6. The use of any one of claims 1-4, wherein R_6 is acetyl.

7. The use of any one of claims 1-4, wherein the compound of Formula I is selected from:




and




.

8. The use of any one of claims 1-4, wherein the compound of Formula I is:




or a pharmaceutically acceptable salt thereof.

9. The use of any one of claims 1-4, wherein the compound of Formula I is:




10. The use of any one of claims 1-4, wherein R_1, R_3 and R_5 are each chloro, and R_2, R_4 and R_6 are each H.
11. The use of any one of claims 1-4, wherein R_1, R_3 and R_5 are each trifluoromethyl, and R_2, R_4 and R_6 are each H.
12. The use of any one of claims 1-4, wherein R_6 is the residue of an amino acid.
13. The use of any one of claims 1-4, wherein R_6 is a 5 to 6-membered non-aromatic heterocyclic ring-carbonyl group.
14. The use of any one of claims 1-4, wherein R_6 is a N,N-di-substituted carbamoyl group, wherein two substituents of said carbamoyl group may combine to each other, together with the nitrogen atom to which they bind, to form a nitrogen-containing heterocyclic group which may be substituted.
15. The use of any one of claims 1-4, wherein R_6 is a (morpholin-4-yl)carbonyl group.
16. The use of any one of claims 1-4, wherein R_6 is a phosphono, which may be substituted or unsubstituted.
17. The use of claim 16, wherein R_6 is $-P(=O)(OH)_2$.
18. The use of any one of claims 1-4, wherein the compound of Formula I is:




or a pharmaceutically acceptable salt thereof.


19. The use of any one of claims 1-4, wherein the compound of Formula I is:



20. The use of any one of claims 1-4, wherein the compound of Formula I is:



21. The use of any one of claims 1-4, wherein the compound of Formula I is:



or a pharmaceutically acceptable salt thereof and the compound or pharmaceutically acceptable salt thereof is dissolved in a pharmaceutically acceptable solution.

22. The use of any one of claims 1 or 4-21, wherein the transplant rejection is consequent to an autograft, a syngeneic graft, an isograft, an allograft, or a xenograft.

23. The use of any one of claims 1 or 4-21, wherein the transplant rejection is consequent to a cell transplant.

24. The use of claim 23, wherein the cell transplant is a hematopoietic stem cell transplant, lymphocyte transplant, or pancreatic islet cell transplant.

25. The use of any one of claims 1 or 4-21, wherein the transplant rejection is consequent to a tissue transplant.

26. The use of claim 25, wherein the tissue is bone, tendon, cartilage, connective tissue, skin, cornea, sclera, heart valve, nerve, or vessel.

27. The use of any one of claims 1 or 4-21, wherein the transplant rejection is consequent to transplant of an organ or a portion thereof.

28. The use of claim 27, wherein the organ is a kidney, the liver, the pancreas, a lung, the heart, the thymus, the intestine, or the uterus.

29. The use of any one of claims 1 or 4-21, wherein the transplant rejection is consequent to a face, limb, eye, trachea, muscle, or esophagus transplant.

30. The use of any of claims 1 or 4-29, wherein the transplant rejection is hyperacute or accelerated rejection.

31. The use of any one of claims 1 or 4-29, wherein the transplant rejection is acute rejection.

32. The use of any one of claims 1 or 4-29, wherein the transplant rejection is chronic rejection.

33. The use of any one of claims 1 or 4-32, wherein the compound of Formula I is to be administered parenterally.

34. The use of claim 33, wherein the compound of Formula I is to be administered by injection.

35. The use of claim 34, wherein the compound of Formula I is to be administered intravenously.

36. The use of any one of claims 1 or 4-35, wherein another treatment for transplant rejection is to be administered concurrently or sequentially.

37. The use of claim 36, wherein an immunosuppressant, a calcineurin inhibitor, a purine metabolism inhibitor, a rapamycin, an immunosuppressive Ig, a monoclonal antibody, or an agent that inhibits T-cell costimulatory pathways, or a combination thereof is to be administered concurrently or sequentially.

38. The use of any one of claims 1 or 4-37 further comprising induction of chimerism using nonmyeloablative pretransplantation treatment.

39. The use of any one of claims 1 or 4-38 further comprising total body irradiation.

40. The use of any one of claims 1 or 3-39, wherein the patient is human.

41. The use of any one of claims 1 or 4-40, wherein the compound of Formula I is to be administered prior to transplantation to the transplant donor.


42. The use of any one of claims 1 or 4-41, wherein the compound of Formula I is to be administered prior to transplantation to the transplant recipient.

43. The use of any one of claims 1 or 4-42, wherein the compound of Formula I is to be administered contemporaneously with transplantation to the transplant recipient.

44. The use of any one of claims 1 or 4-43, wherein the compound of Formula I is to be administered after transplantation to the transplant recipient.

45. The use of claim 44, wherein the compound of Formula I is to be administered for 1 month or less after the transplant to the transplant receipient.

46. A preservation solution for preservation of a cell, tissue, or organ comprising a compound of Formula I:




Formula I

wherein R_1, R_2, R_3, R_4, and R_5 are selected from H, halogen, halogenated C_{1-4} alkyl, and cyano; and

R_6 is H;

or a pharmaceutically acceptable salt, prodrug, or pharmaceutically acceptable salt prodrug thereof.

47. The preservation solution of claim 49, wherein the preservation solution comprises



or a pharmaceutically acceptable salt thereof.

48. The preservation solution of claim 50, wherein the preservation solution comprises

